11:42
Strattera vs Wellbutrin: The Non-Stimulant ADHD SHOWDOWN!
TheKicksShrink
Overview
This video explains the distinct mechanisms and appropriate use cases for Strattera and Wellbutrin as non-stimulant ADHD medications. It emphasizes that these drugs fail differently and highlights a three-filter framework (target symptoms, comorbidities, side-effect tolerance) to guide selection. The presenter, Dr. Sulman Aziz Mirza, uses real-world scenarios to illustrate when Strattera is better for 'hot' or anxious systems and Wellbutrin for 'flat' or depressed systems, cautioning against common pitfalls like mistaking activation for focus and quitting too early. The core message is to match the medication to the individual's specific neurobiological profile to avoid wasted time and treatment derailment.
How was this?
Save this permanently with flashcards, quizzes, and AI chat
Chapters
- Strattera and Wellbutrin, unlike stimulants, have distinct failure modes that can lead to wasted treatment time.
- Choosing the wrong non-stimulant can derail overall treatment progress for weeks or months.
- A structured framework is essential to avoid guesswork when selecting between these medications.
- Understanding individual symptom profiles and medication responses is crucial for effective treatment.
This section sets the stage by highlighting the high stakes of choosing a non-stimulant ADHD medication, emphasizing that a wrong choice leads to significant delays and frustration.
The speaker mentions patients waiting weeks, enduring side effects, only to find their focus barely improved, illustrating the problem of ineffective non-stimulant treatment.
- Filter One: Identify the primary target symptom (inattention, impulsivity, emotional reactivity, morning inertia).
- Filter Two: Leverage comorbidities that can be treated simultaneously (anxiety, depression, nicotine use, sleep issues).
- Filter Three: Assess personal side-effect tolerance (blood pressure, sexual side effects, fatigue, insomnia).
- Crucially, understand medication timeline and dose ceiling to avoid premature discontinuation.
This framework provides a systematic approach to medication selection, moving beyond trial-and-error to a more personalized and efficient treatment strategy.
The speaker outlines how to set a timeline and track both subjective (focus) and objective (task starts) metrics before deciding to pivot from a medication.
- Strattera works by stabilizing attention through reducing emotional noise and increasing norepinephrine tone, rather than stimulating.
- It is often a better choice for individuals whose ADHD is accompanied by anxiety or irritability, as it doesn't exacerbate these symptoms.
- Strattera is suitable for those who experienced jitters or wired feelings with stimulants.
- Success requires patience for the medication to reach a therapeutic dose and steady state, often taking weeks.
Understanding Strattera's stabilizing mechanism is key to appreciating its role in managing ADHD, especially when emotional dysregulation is prominent.
Strattera is recommended when anxiety is a baseline passenger, as it aims to lower emotional static rather than increase arousal.
- Wellbutrin boosts drive, mood, and energy by affecting dopamine and norepinephrine, but it does not 'regulate' in the same way as Strattera.
- It is effective for ADHD symptoms linked to depression, low motivation, or lethargy.
- Wellbutrin also offers a dual benefit for individuals struggling with nicotine dependence.
- A significant risk is that Wellbutrin can worsen pre-existing anxiety, leading to a feeling of being 'wired but not focused'.
This section clarifies Wellbutrin's distinct action as a mood and energy enhancer, differentiating it from Strattera's stabilizing effect and highlighting its potential risks for anxious individuals.
Wellbutrin is presented as the medication of choice when depression is dragging down attention, effectively 'flipping the lights back on'.
- Scenario 1 (Hot System: ADHD + Anxiety): Strattera is preferred because it lowers emotional static and reduces overall system arousal.
- Scenario 2 (Flat System: ADHD + Depression/Nicotine Use): Wellbutrin excels at lifting mood and energy, addressing the core issue of low drive.
- Scenario 3 (Stimulant Intolerance): Strattera provides steady, 24-hour coverage without stimulant-like side effects; Wellbutrin can be an add-on if depression is also present.
- The key is to identify if your system runs 'hot,' 'flat,' or is sensitive to stimulants.
These scenarios provide practical, relatable examples that help learners apply the three-filter framework to their own experiences and make informed decisions.
For someone with ADHD and anxiety ('hot system'), Wellbutrin might worsen the feeling of being 'on alert,' whereas Strattera would aim to calm the system.
- The decision between Strattera and Wellbutrin should be based on whether your system is hot, flat, or sensitive, not on guesswork.
- Track key metrics and set clear timelines to adjust treatment with confidence.
- Avoid mistaking activation for improved executive function.
- While effective, these non-stimulants are often second-line treatments after stimulants, used when stimulant rules change.
This concluding section reinforces the core message of intentional, data-driven treatment selection and provides actionable advice for managing ADHD medication trials effectively.
The speaker advises asking 'Is your system hot, flat, or sensitive?' as the primary question to guide medication choice.
Key takeaways
- Strattera and Wellbutrin have fundamentally different mechanisms and are suited for different ADHD symptom profiles and co-occurring conditions.
- Effective non-stimulant treatment requires patience, as both Strattera and Wellbutrin take time to reach therapeutic effect.
- Wellbutrin can worsen anxiety, while Strattera is often better tolerated by individuals with high baseline anxiety or irritability.
- Wellbutrin is a strong option for ADHD when depression or low motivation is a primary driver, whereas Strattera is better for stabilizing emotional reactivity.
- Mistaking physical activation or feeling 'wired' for improved focus is a common pitfall that leads to premature discontinuation of effective treatment.
- A systematic approach using target symptoms, comorbidities, and side-effect tolerance is more effective than trial-and-error for selecting non-stimulant ADHD medication.
- Tracking both subjective feelings and objective performance metrics is crucial for evaluating medication effectiveness during a trial period.
Key terms
Non-stimulant ADHD medicationStrattera (atomoxetine)Wellbutrin (bupropion)NorepinephrineDopamineEmotional reactivityComorbiditiesTherapeutic ceilingSteady stateActivation vs. Executive Function
Test your understanding
- How do Strattera's mechanism of action and typical patient response differ from Wellbutrin's?
- What are the three key filters recommended for choosing between Strattera and Wellbutrin, and why is each important?
- Under what specific symptom profiles or co-occurring conditions would Strattera be the preferred non-stimulant choice?
- When might Wellbutrin be a more appropriate non-stimulant option for ADHD, and what is its primary risk?
- How can understanding the concepts of 'activation' versus 'executive function' help prevent misinterpreting medication effects?